Aims: To determine whether baseline metabolic syndrome (MetS) modifies the effect of intensive blood pressure control on cardiovascular (CV) outcomes, and whether the effects varied by race/ethnicity.
| INTRODUCTION
Hypertension is a well-established independent risk factor for cardiovascular disease (CVD); however, it is not clear how to individualize targets to maximize benefits among subgroups of patients with differing risk factors. It is well recognized that the cluster of risk factors encompassing metabolic syndrome (MetS) is a strong early predictor of both type 2 diabetes 1,2 and CVD. [2] [3] [4] [5] [6] In particular, racial differences in MetS components, including hypertension, obesity, dysglycaemia and dyslipidaemia have been well documented, [7] [8] [9] and contribute to disparities in CVD outcomes. [10] [11] [12] Recently, the Systolic Blood Pressure Intervention Trial (SPRINT) was conducted among a multiethnic/multiracial cohort of 9361 participants without diabetes randomized to intensive (<120 mm Hg) or standard (<140 mm Hg) systolic blood pressure (SBP) control. 13 The study was terminated early after demonstrating a 25% reduction in the primary composite outcome (myocardial infarction, acute coronary syndrome, stroke, heart failure or cardiovascular [CV] death) and a 27% reduction in all-cause mortality in the intensive compared with the standard group. The study population included 30% non-Hispanic black people and 11% Hispanic people. 14, 15 The initial analysis did not identify significant racial (black vs non-black) differences in benefit of intensive SBP control on the primary CVD outcome in a prespecified subgroup analysis; however, the influence of metabolic status on the CVD outcomes was not addressed.
The possibility that treatment heterogeneity may exist among patients with varying metabolic manifestations was suggested by findings from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study. Although only half the size of SPRINT, ACCORD reported no significant benefit in a similar SBP comparison in participants with well-established type 2 diabetes and reported a higher rate of serious adverse events attributed to the intervention. 16 A recent Cochrane meta-analysis concluded that there was insufficient evidence to recommend more intensive blood pressure management compared with standard control in patients with diabetes, although this was based heavily on the ACCORD study findings. 17 The objective of the present analysis was to determine whether baseline MetS is associated with the response to intensive blood pressure control and whether the response differs among the racial and ethnic populations in the SPRINT cohort.
| MATERIALS AND METHODS

| Population
SPRINT enrolled 9361 participants without diabetes at high CVD risk, aged ≥50 years, at 102 clinical centres. Extensive descriptions of the study rationale, design, procedures and biochemical assays have been published previously. 13, [18] [19] [20] The median follow-up period was 3.26 years.
Patients were randomly assigned to an SBP target of either <120 
| Study measures
Demographic data were collected at baseline while clinical and laboratory data were collected at baseline and every 3 months.
MetS was defined using the National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III criteria. 21 The exception was that body mass index (BMI) was substituted for waist circumfer- We calculated BMI as body weight (kg) divided by height (m). Race-adjusted eGFR was calculated using the MDRD formula, 24, 25 and the eGFR was categorized as ≥ or <60 mL/min/1.73 m 2 . (Table 1) , and by treatment arm within race/ethnicity groups ( Table 2 ). Statistical differences between MetS groups were compared using t-tests and chi-squared tests. Differences between subgroups were assessed using one-way analysis of variance and chisquared tests. Post-treatment SBP was estimated across the entire follow-up period from 6 to 48 months using a general linear model with random effects to account for within-participant correlation.
| Statistical analyses
Effect of treatment arm assignment on time to the first event within
MetS stratum (ie, primary CVD outcome, mortality and primary outcome or death) was analysed based on the intention-to-treat approach using
Cox proportional hazards regression models, with two-sided tests at the 5% level of significance and stratification by clinical site. Two-way interactions between treatment effect and MetS group were assessed using likelihood-ratio tests and Hommel's technique to adjust for multiple comparisons. 26 Analysis of time-to-event outcomes by race/ethnicity within baseline MetS groups was performed in an analogous manner. Additional Cox models were fitted including age, gender and baseline eGFR as covariates. Appropriateness of the proportional hazards assumption was evaluated graphically by examining martingale residuals and Kolmogorov-type supremum tests. 27 If warranted, a Heaviside function was employed to adjust estimates for non-proportionality. 28 Product-limit survival estimates were used to make cumulative hazards plots for the primary CVD outcome and all-cause mortality by MetS status. All analyses were performed using SAS version 9.4 software (SAS Institute, Inc., Cary, North Carolina).
3 | RESULTS
| Baseline characteristics by MetS status
Our study population included 2802 NHB (30%), 984 Hispanic (11%), and 5399 NHW participants (58% Table S1 . In both treatment groups, participants with MetS were significantly younger, more likely to self-identify as Hispanic, and less likely to self-identify as NHB.
Although all SPRINT participants met the blood pressure criterion for MetS, by definition, baseline SBP was significantly lower and DBP was significantly higher in the MetS groups of both study arms. Participants with MetS in both study arms were also prescribed a greater number of antihypertensive agents at baseline compared with those without MetS.
There were significant differences in all non-blood pressure MetS components across MetS subgroups (Table S1 ).
| Baseline characteristics among participants within MetS subgroups, by race/ethnicity
Participants with MetS were further stratified by treatment arm within each race/ethnicity group (Table S2) There were significant differences across racial/ethnic groups in participants with MetS at baseline, as expected (Table S3) . Notably, NHW participants were older, less likely to be female, and had lower DBP, lower renal function, more baseline clinical CVD, fewer never smokers, lower total cholesterol, and more statin use than NHB or Hispanic participants in both treatment groups. Likewise, among patients without MetS, there were baseline differences among race/ ethnicity subgroups, including older age, a lower frequency of women, lower renal function, more baseline clinical CVD, lower total cholesterol, higher fasting glucose, and more statin use in NHW compared with NHB or Hispanic participants in both treatment groups (Table S4 ).
| Mortality and CV events
In participants with MetS at baseline, the estimated mean SBP after 6 months of treatment was 121.7 (95% confidence interval Table 2 shows univariable effects of intensive vs standard SBP treatment arm assignment and Cox proportional hazards models fitted to time to first CV event and mortality outcomes.
Results are shown stratified by baseline MetS status. There were Figure 1A ). The nominal P values for differences in the HR across racial/ethnic groups for all-cause mortality were marginally significant ( Figure 1B) ; however, they did not remain significant after adjustment for multiple comparisons (Hommel adjusted P-value .47 in the MetS group and .36 in the no MetS group, respectively). Similar results were observed after adjusting models for baseline gender, eGFR and age, as well as models adjusting for baseline differences in BMI, SBP, subclinical CVD, and smoking status (data not shown). 
| DISCUSSION
MetS is common among patients with hypertension and is a significant predictor of CV events as well as mortality. In the present analysis, the beneficial effect of intensive SBP treatment on the primary CV outcomes, including mortality, was similar in participants with and without MetS, and did not differ among race/ethnicity subgroups.
This finding extends the observations from the main SPRINT study, in which no significant treatment heterogeneity was observed among prespecified baseline subgroups, including chronic kidney disease, age, gender, race, previous CV disease or SBP. 13 A summary of key findings is shown in Table 3 . In the subgroup without MetS at baseline there appears to be late separation (after 2 years' follow-up)
between intensive and standard SBP arms for both primary CV event and all-cause mortality; however, the treatment-specific event rates Abbreviations: B/L, baseline; CL, confidence limit. *P value adjusted for multiple comparisons. HRs and tests of treatment × subgroup interaction from univariable proportional hazards models.
in the 2 MetS subgroups were similar over the entire course of follow-up.
The results provide insight regarding the efficacy of intensive blood pressure-lowering efforts across the spectrum of metabolic dis- • MetS was highly prevalent in the SPRINT study cohort (39% of the study population).
• The CV benefit of intensive blood pressure control was similar between patients with and without MetS.
• The CV mortality and all-cause mortality benefit of intensive blood pressure control was similar between patients with and without MetS.
• The effect of baseline MetS on the efficacy of intensive SBP control did not differ across categories of self-reported race/ethnicity. addition, patients were selected for higher CV risk in order to ensure adequate power, and outcomes were prospectively adjudicated. A number of limitations should also be considered. First, the diagnosis of diabetes for eligibility purposes was based on clinical history and fasting glucose, not by more sensitive measures such as the oral glucose tolerance test. Moreover, we did not have formal measures of insulin sensitivity, or waist circumference which could have further elucidated the extent of metabolic derangements and underlying racial/ethnic differences. Regardless, it is possible that follow-up was too short for metabolic effect to manifest. In addition, there was less representation of Hispanic ethnicity compared with NHB or NHW ethnicity and negligible representation from other backgrounds.
Importantly, the results may not be generalizable to younger patients, patients with relatively low CV risk, and patients with extensive comorbidities. Thus, additional study is needed in these groups.
Finally, there are concerns that the blood pressure measurement technique used in SPRINT would result in systematically lower blood pressures than that obtained with typical clinical practice. 35, 36 While this would potentially result in overtreatment if similar SBP targets are pursued in clinical practice, it is unlikely to obscure differences between those with and without MetS in their response to more intensive blood pressure-lowering.
In conclusion, intensive SBP control was associated with lower CVD rates compared with the standard SBP control, and the results were consistent in individuals without diabetes with and without
MetS and regardless of race (black vs non-black) or Hispanic ethnicity. The findings support intensive blood pressure control for patients with a metabolic status between normoglycaemia and diabetes, regardless of race or ethnicity.
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